caa a22 4500 445315377 CHVBK 20180317142645.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1007/s10552-010-9713-4 doi (NATIONALLICENCE)springer-10.1007/s10552-010-9713-4 The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer [Elektronische Daten] [Jay Fowke, Saundra Motley, Daniel Barocas, Michael Cookson, Raoul Concepcion, Susan Byerly, Joseph Smith Jr] Objective: Prior studies report statins may reduce the risk of advanced prostate cancer. This study investigates the association between statin use and the likelihood of having a PSA or DRE test, blood PSA levels, prostate volume, and the severity of lower urinary tract symptoms. We also describe the association between statin use and prostate cancer and high-grade prostatic intraepithelial neoplasia (PIN) before and after controlling for prostate cancer screening indices associated with statin use. Methods: The Nashville Men's Health Study used a multicenter, rapid recruitment protocol to collect clinical, biologic, behavioral, and body measurement data from 2,148 men 40years or older scheduled for diagnostic prostate biopsy. Medication use and other data were ascertained by research survey, clinical interview, and chart review. Results: Approximately 37% of participants were taking a statin. Statin use was significantly associated with a 12% lower PSA levels and 8% smaller prostate volume after controlling for age, race, BMI, WHR, aspirin use, and other comorbidity. Simvastatin was more strongly associated with prostate volume, while atorvastatin was associated with PSA. Statin use was marginally associated with increasing PSA test frequency among men with undiagnosed cancer. Statin use was not associated with the frequency or results of digital rectal exams, lower urinary tract symptom severity, high-grade (Gleason>6) prostate cancer (OR=0.95 (0.73, 1.24)), low-grade (Gleason=6) prostate cancer (OR=1.11 (0.86, 1.42)) or PIN (OR=0.82, (0.57, 1.17)). Additional control for the number of prior PSA tests, PSA levels, and prostate volume did not alter these results. Conclusion: These results suggest selective referral for biopsy associated with statin use is an essential element to address in further understanding the potential for statins to prevent prostate cancer. Springer Science+Business Media B.V., 2010 Prostate cancer nationallicence PSA nationallicence Statin nationallicence Prostate volume nationallicence Bias nationallicence Fowke Jay Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Ave. 6th Floor, Suite 600, 37203-1738, Nashville, TN, USA aut Motley Saundra Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Ave. 6th Floor, Suite 600, 37203-1738, Nashville, TN, USA aut Barocas Daniel Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut Cookson Michael Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut Concepcion Raoul Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut Byerly Susan Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Ave. 6th Floor, Suite 600, 37203-1738, Nashville, TN, USA aut Smith Jr Joseph Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut Cancer Causes & Control Springer Netherlands 22/3(2011-03-01), 417-426 0957-5243 22:3<417 2011 22 10552 https://doi.org/10.1007/s10552-010-9713-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-010-9713-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fowke Jay Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Ave. 6th Floor, Suite 600, 37203-1738, Nashville, TN, USA aut NATIONALLICENCE 700 1- Motley Saundra Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Ave. 6th Floor, Suite 600, 37203-1738, Nashville, TN, USA aut NATIONALLICENCE 700 1- Barocas Daniel Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut NATIONALLICENCE 700 1- Cookson Michael Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut NATIONALLICENCE 700 1- Concepcion Raoul Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut NATIONALLICENCE 700 1- Byerly Susan Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Ave. 6th Floor, Suite 600, 37203-1738, Nashville, TN, USA aut NATIONALLICENCE 700 1- Smith Jr Joseph Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/3(2011-03-01), 417-426 0957-5243 22:3<417 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer